Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.51 |
| ▸ | FGFR3 | P22607 | 13/20 | 0.51 |
| ▸ | FYN | P06241 | 3/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021815 | 0.89 | KDR (0.50) | KDRFGFR3FYN | |
| SCHEMBL3025894 | 0.88 | KDR (0.50) | KDRFGFR3FYNPIK3CDPIK3R1 | |
| SCHEMBL3021089 | 0.86 | KDR (0.51) | KDRFGFR3FYNPIK3CDPIK3R1 | |
| SCHEMBL3031389 | 0.80 | FYN (0.71) | KDRFGFR3FYNPIK3CDPIK3R1 | |
| SCHEMBL3026704 | 0.79 | KDR (0.65) | KDRFGFR3FYNPIK3CDPIK3R1 | |
| SCHEMBL3027808 | 0.78 | FLT3 (0.52) | KDRFGFR3 | |
| SCHEMBL27789898 | 0.78 | KDR (0.49) | KDRFGFR3FYNPIK3CDPIK3R1 | |
| SCHEMBL3026843 | 0.77 | GABRA1 (0.48) | KDRFGFR3 | |
| SCHEMBL27789894 | 0.76 | KDR (0.43) | KDRFGFR3 | |
| SCHEMBL3033051 | 0.75 | FLT3 (0.44) | KDRFGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101827844-B | Imidazo [1,2-a] pyridine derivatives useful as ALK inhibitors | NOVARTIS AG | 2013-08-14 | — | — | CN | disclosed |
| US-8367662-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-02-05 | — | — | US | disclosed |
| EP-2212323-B1 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| CN-101827844-A | Imidazo [1,2-a] pyridine derivatives useful as ALK inhibitors | NOVARTIS AG | 2010-09-08 | — | — | CN | disclosed |
| US-20100210641-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-08-19 | — | — | US | disclosed |
| EP-2212323-A2 | IMIDAZO [1,2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| WO-2009050183-A2 | IMIDAZO [1, 2-A] PYRIDINE DERIVATIVES USEFUL AS ALK INHIBITORS | NOVARTIS AG (CH) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210641-A1 | Organic Compounds | ALK, ACVR1, ACVRL1 | KDR 372/4885FGFR3 32/4885FYN 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.